Androgenetic Alopecia (AGA); Healthy Volunteers - Male and Female
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Anti-PRLR antibody with extended half-life. HEADLINE Phase 1/2a trial in PHL ongoing (interim Phase 1 data reported June 2026); Phase 2 trial in endometriosis anticipated to initiate Q4 2026.
ABS-202
Preclinical · ActiveModality: antibody
Target PRLR (prolactin receptor)
Indications
undisclosed immunology and inflammation indication(Preclinical)
Status note Second novel anti-PRLR antibody program, designed via generative AI platform; indication undisclosed.
ABS-101
Stage not disclosed · ActiveModality: antibody
Target TL1A
Indications
inflammatory bowel disease (IBD)(Stage not disclosed)
Status note Mentioned only in the 10-K competitive landscape section as a TL1A-targeting candidate; stage not stated in the filings reviewed.
ABS-301
Preclinical · Active
Indications
oncology (indication not specified)(Preclinical)
Status note Potential first-in-class oncology asset discovered through the company's reverse immunology platform; per 10-K business section.
ABS-501
Preclinical · Active
Target HER2
Indications
HER2-expressing cancers (indication not specified)(Preclinical)
Status note Potentially differentiated HER2 program; per 10-K business section.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Androgenetic Alopecia (AGA); Healthy Volunteers - Male and Female
—
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.